{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzoibq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzoibq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/45\\\/24\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/45\\\/24\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/45\\\/24\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/45\\\/24\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EVenous thromboembolism (VTE) is a common problem, at a prevalence of 1 to 2 VTEs per 1000 patients, with an in-hospital fatality rate of up to 12%. This article discusses novel oral anticoagulants that have become available for treatment over the past 5 years, the prevention of recurrent VTE, and thrombolytic therapy for the treatment of acute pulmonary embolism.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EThrombotic Disorders\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EThromboembolic Disease\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EThrombotic Disorders\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EThromboembolic Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EPulmonary \u0026amp; Respiratory Medicine\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EVenous thromboembolism (VTE) is a common problem, at a prevalence of 1 to 2 VTEs per 1000 patients, with an in-hospital fatality rate of up to 12%. Victor F. Tapson, MD, Cedars-Sinai Medical Center, Los Angeles, California, USA, discussed the 3 novel oral anticoagulants (NOACs) that have become available for the treatment of VTE over the past 5 years.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EAs of October 2014, the US Food and Drug Administration (FDA) has approved the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban and apixaban for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE). These agents\u2014as well as edoxaban, a factor Xa inhibitor that is under consideration by the FDA as of November 2014\u2014have similar pharmacologic characteristics, including some metabolism by cytochrome P450 family members and transport by P-glycoprotein.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EAll the NOACs have at least some protein binding in circulation; however, less protein binding occurs with dabigatran (35%) [Blech S et al. \u003Cem\u003EDrug Metab Dispos\u003C\/em\u003E. 2008], with the implication that, unlike the other NOACs, it is dialyzable, which may be important if a bleed occurs. Dr Tapson also pointed out that renal clearance is a relevant patient characteristic to be aware of when using the NOACs. Apixaban has the lowest renal clearance, 25% [Raghavan N et al. \u003Cem\u003EDrug Metab Dispos\u003C\/em\u003E. 2009], whereas dabigatran has the highest amount, \u2264 80% [Stangier J et al. \u003Cem\u003EBr J Clin Pharmacol\u003C\/em\u003E. 2007]. Pivotal trials for the NOACs are listed in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/15516\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/15516\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/15516\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n            \u003Cp id=\u0022p-5\u0022 class=\u0022first-child\u0022\u003EPivotal Trials for Novel Oral Anticoagulants\u003C\/p\u003E\n         \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-6\u0022\u003EThe rates of the primary end point of recurrent VTE\u2014whether DVT or PE\u2014were similar among the NOACs and were noninferior to warfarin. In general, the NOACs resulted in less severe bleeding when compared with that of warfarin in the pivotal trials, and rivaroxaban and apixaban achieved superiority over warfarin for incidence of major bleeding.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EDr Tapson discussed NOAC drug-drug interactions, noting that clinicians should be aware that strong CYP3A4 inhibitors combined with P-glycoprotein inhibitors should be avoided. For example, carbamazepine, phenytoin, rifampin, and St John\u0027s wort should be avoided with rivaroxaban and apixaban, whereas concomitant P-glycoprotein inducers such as rifampin should be avoided with dabigatran. Furthermore, when used for the treatment of VTE, dabigatran and rivaroxaban should be avoided in patients with a creatinine clearance \u0026lt; 30 mL\/min, and apixaban should be used with caution.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003ERichard N. Channick, MD, Massachusetts General Hospital, Boston, Massachusetts, USA, discussed the prevention of recurrent VTE. Thirty percent of patients will experience VTE recurrence by 10 years, with the greatest risk occurring 6 to 12 months after acute VTE. Long-term anticoagulation is highly effective in preventing VTE recurrence but must be balanced with an increased risk of bleeding. In addition, there is a risk of VTE recurrence after discontinuation of anticoagulation, which is most likely in the first 2 to 3 months after discontinuation. Dr Channick outlined 3 phases of anticoagulation: the initial phase, which lasts for 5 to 7 days and is the period associated with the greatest risk of VTE recurrence; the long-term phase, which lasts from 7 days to 3 months and is the minimum recommended amount of time for anticoagulation; and the extended phase, which is \u0026gt; 3 months.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EDetermining a patient\u0027s risk of recurrence is based on his or her characteristics, the presence of risk factors, and the nature of the original VTE. For example, if the initial VTE was PE, the patient is more likely to have a PE recurrence than a proximal DVT. Risk factors for VTE recurrence include age, PE as the index event, and elevated D-dimer. It is also important to consider a patient\u0027s risk of bleeding.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EThere are 3 types of patients, each with a different anticoagulation recommendation. In patients with a transient risk factor, anticoagulation can be discontinued after 3 months, whereas patients with an ongoing risk factor, such as cancer, should receive continued anticoagulation.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EIn patients who experience an unprovoked VTE, anticoagulation should be continued for at least 3 months and then reconsidered on the basis of a risk-benefit analysis and the patient\u0027s preference.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EIn addition to the NOACs and warfarin, aspirin can be used to prevent VTE recurrence. In 2 randomized controlled trials, 100 mg\/d of aspirin reduced the relative risk of experiencing VTE recurrence with a low rate of bleeding [Becattini C et al. \u003Cem\u003EN Engl J Med.\u003C\/em\u003E 2012; Brighton TA et al. \u003Cem\u003EN Engl J Med.\u003C\/em\u003E 2012].\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003ESusan Murin, MD, MSc, University of California, Davis, Sacramento, California, USA, discussed thrombolytic therapy for the treatment of acute PE. Currently, there are 3 agents approved by the FDA for thrombolysis in PE: streptokinase, urokinase, and tissue plasminogen activator (alteplase). Although thrombolysis dissolves the clot, it is associated with an increased risk of bleeding. In addition, it is unknown whether the short-term improvement in hemodynamics and perfusion in patients treated with thrombolysis translates into long-term meaningful outcomes.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EUltrasound-assisted catheter-directed thrombolysis plus heparin resulted in greater improvements when compared with heparin alone in 1 study [Kucher N et al. \u003Cem\u003ECirculation\u003C\/em\u003E. 2014]. In addition, the rate of bleeding was comparable to that observed in trials that evaluated systemic thrombolysis.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EDr Murin suggested that thrombolysis be routinely used in patients with PE and shock who do not have contraindications. In addition, thrombolysis should be considered but not routinely administered in patients with intermediate risk for PE. Finally, systemic thrombolysis is preferred over catheter-directed thrombolysis in patients who have an average risk of bleeding.\u003C\/p\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/45\/24.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzoibq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzoibq\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}